Abstract
A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcinoma.
Key words: Refractory metastatic breast cancer, Mitomycin C, Vindesine, Melphalan
Abbreviations
- MMC
mitomycin C
- VDS
vindesine
- L-PAM
melphalan
References
- Brambilla C, Zambetti M, Ferrari L, Bonadonna G (1989) Mitomycin C and vinblastine in advanced refractory breast cancer. Tumori 75:141–144 [DOI] [PubMed] [Google Scholar]
- Buzdar A, Ross M, Smith T, Blumenschein G, Hortobagyi G, Eckles N, Gehan E, Freireich E (1983) Improved survival in metastatic breast cancer treated with combination chemotherapy — an experience of past 3 decades. Proceedings 13th International Congress of Chemotherapy, Wien August 28-September 2, part 244/1
- Carbone PP, Bauer M, Band B, Tormey D (1977) Chemotherapy of disseminated breast cancer: current status and prospects. Cancer 39:2916–2922 [DOI] [PubMed] [Google Scholar]
- Carter SK (1976) Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 3:141–174 [DOI] [PubMed] [Google Scholar]
- Creech RH, Catalano RB, Shah MK, Dayal H (1982) A randomized trial of Adriamycin vs mitomycin at low doses in CMF-refractory metastatic breast cancer patients. Proc Am Soc Clin Oncol Annu Meet C-342:88 [Google Scholar]
- Creech RH, Catalano RB, Shah MK, Dayal H (1983) Effective low-dose mitomycin regimen for hormonal and chemotherapy refractory patients with metastatic breast cancer. Cancer 51:1034–1040 [DOI] [PubMed] [Google Scholar]
- Cutler S, Myers MH, Green SB (1975) Trends in survival rates in patients with cancer. N Engl J Med 293:122–124 [DOI] [PubMed] [Google Scholar]
- De Lena M (1987) Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy. Tumori 66:481–487 [DOI] [PubMed] [Google Scholar]
- Denefrio JM, East DM, Troner MB, Vogel CL (1978) A phase II study of mitomycin-C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic chemotherapy. Cancer Treat Rep 62:2113–2115 [PubMed] [Google Scholar]
- Doll DC, Weiss RB, Issel BF (1985) Mitomycin-C: ten years after approval for marketing. J Clin Oncol 3:276–291 [DOI] [PubMed] [Google Scholar]
- Fleishman GB, Yap HI, Bodey GP, Chuang VP, Blumenschein GR (1982) Comparability in therapeutic index with continuous 5-day infusion of vinblastine for refractory breast cancer. Proc Am Soc Clin Oncol Annu Meet C-316, 82 [Google Scholar]
- Garewal HS, Brooks RJ, Jones SE, Miller TP (1983) Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. J Clin Oncol 1:773–775 [DOI] [PubMed] [Google Scholar]
- Godfrey TE (1979) Mitomycin C in breast cancer. In: Carter SK, Crooke ST (eds) Mitomycin C: current status and new developments. Academic Press, New York, pp 91–99 [Google Scholar]
- Hansen PV, Brincker H (1984) Vindesine in the treatment of metastatic breast cancer. Eur J Cancer Clin Oncol 20:1221–1225 [DOI] [PubMed] [Google Scholar]
- Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM (1979) Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG. Cancer 43:1225–1233 [DOI] [PubMed] [Google Scholar]
- Konitis PH, Aisner J, Van Echo DA, Lichtenfeld K, Wiernik P (1981) Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 48:1295–1298 [DOI] [PubMed] [Google Scholar]
- Millan J, Daniels M, Lluch A (1987) Mitomycin C, vindesine and aminoglutethimide in refractory breast cancer. Proc. 4th EORTC Breast Cancer Working Conference, London 30th June –3th July, F2.21 GLG Marketing, Sussex, England
- Morgenfeld EL, Rivarola EG, Negro A, Requejo H, Suzlovich Z, Senatore V, Williams B, Gercovich FG (1988) Vindesine for recurrent metastatic breast cancer (abstract). Proc Am Soc Clin Oncol Annu Meet 21
- Palmeri S, Gebbia V, Russo A, Gebbia N, Rausa L (1990) Ineffectiveness of mitomycin C plus nitrosoureas in the treatment of refractory metastatic breast cancer. Int J Exp Clin Chemother 3:168–171 [Google Scholar]
- Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR (1985) Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 56:2381–2384 [DOI] [PubMed] [Google Scholar]
- Pouillart P, Hoang HT, Brugerie E, Lheriter J (1974) Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation. Biomedicine 21:471–479 [PubMed] [Google Scholar]
- Ross MB, Buzdar AU, Smith TL (1979) Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55:341–346 [DOI] [PubMed] [Google Scholar]
- Smith IE, Hedley DW, Powels TJ (1978) Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 62:1427–1433 [PubMed] [Google Scholar]
- Thomas J, Specenier P, Wildiers J (1987) Third line chemotherapy for advanced breast cancer using mitomycin C (MMC) and vinblastine. Proc. 4th EORTC Breast Cancer Working Conference, London 30th June–th July, F2.25
- Todd M, Shoag M, Cadman E (1983) Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol 406–408 [DOI] [PubMed]